Boston to curb insurance coverage of GLP-1 drugs for city workers
The PEC voted unanimously on Tuesday to let the city change its Blue Cross Blue Shield of Massachusetts…
Scaling risk management for renewable power producers
Renewable energy generators rely upon advanced asset optimisation and risk management solutions to enhance operational efficiency and meet…
EU’s answer to Starlink should start up in 2029, commissioner says
BRUSSELS, Jan 27 (Reuters) – The European Union’s multi-orbit array of 290 satellites known as IRIS2 should be…
After 844 Days, Israelis to turn off clock marking time since October 7 attack
Item 1 of 6 A person holding a placard reading “Sometimes dreams come true” sits next to a…
Largest European pension fund ABP cut back US Treasury holdings last year
LONDON, Jan 23 (Reuters) – The value of the U.S. Treasuries held by Dutch pension fund ABP, Europe’s…
Many patients may keep off lost pounds after stopping a GLP-1, US data suggests
Real-world data suggests weight loss durability post-GLP-1 drug discontinuationStudy suggests weight regain may be less common than clinical…
Can you really price global regime change?
ORLANDO, Florida, Jan 20 (Reuters) – U.S. President Donald Trump’s latest foreign policy and trade war salvos are…
Weaker UK jobs data may offer inflation relief to BoE
Private sector pay grows by least since November 2020UK regular wage growth slows to 4.5%Jobless rate holds at…
Israel government sends 2026 budget to parliament, approval at risk from rifts
JERUSALEM, Jan 19 (Reuters) – Israel’s Finance Ministry said on Monday it delivered the 2026 state budget draft…
Trump wants nations to pay $1 billion to stay on his peace board, report says
Jan 17 (Reuters) – The Trump administration wants nations to pay $1 billion to stay on his peace…
Iran’s leader Khamenei accuses Trump of inciting deadly protests
US-based rights group says 3,090 people have been killedInternet blackout reimposed after brief easing of restrictions, monitor saysIran…
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalledTzield pushed back after adverse event…